Structures of Complete Extracellular Assemblies of Type I and Type II Oncostatin M Receptor Complexes

Overview

Journal Nat Commun

Specialty Biology

Date 2024 Nov 12

PMID 39532904

Authors

Yi Zhou

Panayiotis E Stevis

Jing Cao

George Ehrlich

Jennifer Jones

Ashique Rafique

Mark W Sleeman

William C Olson

Matthew C Franklin

Affiliations

Soon will be listed here.

Abstract

Oncostatin M (OSM) is a unique Interleukin 6 (IL-6) family cytokine that plays pivotal roles in numerous biological events by signaling via two types of receptor complexes. While type I OSM receptor complex is formed by glycoprotein 130 (gp130) heterodimerization with Leukemia Inhibitory Factor receptor (LIFR), type II OSM receptor complex is composed of gp130 and OSM receptor (OSMR). OSM is an important contributor to multiple inflammatory diseases and cancers while OSM inhibition has been shown to be effective at reducing symptoms, making OSM an attractive therapeutic target. Using cryogenic electron microscopy (cryo-EM), we characterize full extracellular assemblies of human type I OSM receptor complex and mouse type II OSM receptor complex. The juxtamembrane domains of both complexes are situated in close proximity due to acute bends of the receptors. The rigid N-terminal extension of OSM contributes to gp130 binding and OSM signaling. Neither glycosylation nor pro-domain cleavage of OSM affects its activity. Mutagenesis identifies multiple OSM and OSMR residues crucial for complex formation and signaling. Our data reveal the structural basis for the assemblies of both type I and type II OSM receptor complexes and provide insights for modulation of OSM signaling in therapeutics.

References

Kurth I, Horsten U, Pflanz S, Timmermann A, Kuster A, Dahmen H . Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130. J Immunol. 1999; 164(1):273-82. DOI: 10.4049/jimmunol.164.1.273. View

Chollangi S, Mather T, Rodgers K, Ash J . A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor. J Biol Chem. 2012; 287(39):32848-59. PMC: 3463309. DOI: 10.1074/jbc.M112.387324. View

Metcalfe R, Hanssen E, Fung K, Aizel K, Kosasih C, Zlatic C . Structures of the interleukin 11 signalling complex reveal gp130 dynamics and the inhibitory mechanism of a cytokine variant. Nat Commun. 2023; 14(1):7543. PMC: 10662374. DOI: 10.1038/s41467-023-42754-w. View

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O . Highly accurate protein structure prediction with AlphaFold. Nature. 2021; 596(7873):583-589. PMC: 8371605. DOI: 10.1038/s41586-021-03819-2. View

Adrian-Segarra J, Schindler N, Gajawada P, Lorchner H, Braun T, Poling J . The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation. J Biol Chem. 2018; 293(18):7017-7029. PMC: 5936835. DOI: 10.1074/jbc.RA118.001920. View

Liebschner D, Afonine P, Baker M, Bunkoczi G, Chen V, Croll T . Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol. 2019; 75(Pt 10):861-877. PMC: 6778852. DOI: 10.1107/S2059798319011471. View

Johnsson B, Lofas S, Lindquist G . Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem. 1991; 198(2):268-77. DOI: 10.1016/0003-2697(91)90424-r. View

Ichihara M, Hara T, Kim H, Murate T, Miyajima A . Oncostatin M and leukemia inhibitory factor do not use the same functional receptor in mice. Blood. 1997; 90(1):165-73. View

Williams C, Headd J, Moriarty N, Prisant M, Videau L, Deis L . MolProbity: More and better reference data for improved all-atom structure validation. Protein Sci. 2017; 27(1):293-315. PMC: 5734394. DOI: 10.1002/pro.3330. View

10.

Olivier C, Auguste P, Chabbert M, Lelievre E, Chevalier S, Gascan H . Identification of a gp130 cytokine receptor critical site involved in oncostatin M response. J Biol Chem. 2000; 275(8):5648-56. DOI: 10.1074/jbc.275.8.5648. View

11.

Boulanger M, Bankovich A, Kortemme T, Baker D, Garcia K . Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell. 2003; 12(3):577-89. DOI: 10.1016/s1097-2765(03)00365-4. View

12.

Tseng P, Hoon M . Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med. 2021; 13(619):eabe3037. PMC: 9595590. DOI: 10.1126/scitranslmed.abe3037. View

13.

Pettersen E, Goddard T, Huang C, Couch G, Greenblatt D, Meng E . UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004; 25(13):1605-12. DOI: 10.1002/jcc.20084. View

14.

Lee B, Hogg E, Below C, Kononov A, Blanco-Gomez A, Heider F . Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nat Commun. 2021; 12(1):7336. PMC: 8683436. DOI: 10.1038/s41467-021-27607-8. View

15.

Skiniotis G, Boulanger M, Garcia K, Walz T . Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol. 2005; 12(6):545-51. DOI: 10.1038/nsmb941. View

16.

Punjani A, Rubinstein J, Fleet D, Brubaker M . cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017; 14(3):290-296. DOI: 10.1038/nmeth.4169. View

17.

Dey G, Radhakrishnan A, Syed N, Thomas J, Nadig A, Srikumar K . Signaling network of Oncostatin M pathway. J Cell Commun Signal. 2012; 7(2):103-8. PMC: 3660694. DOI: 10.1007/s12079-012-0186-y. View

18.

Kang S, Narazaki M, Metwally H, Kishimoto T . Historical overview of the interleukin-6 family cytokine. J Exp Med. 2020; 217(5). PMC: 7201933. DOI: 10.1084/jem.20190347. View

19.

Gearing D, Comeau M, Friend D, Gimpel S, Thut C, McGourty J . The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science. 1992; 255(5050):1434-7. DOI: 10.1126/science.1542794. View

20.

Myszka D . Improving biosensor analysis. J Mol Recognit. 1999; 12(5):279-84. DOI: 10.1002/(SICI)1099-1352(199909/10)12:5<279::AID-JMR473>3.0.CO;2-3. View